Medtronic is the world leader in medical technology providing lifelong solutions for people with chronic disease. We offer products, therapies and services that enhance or extend the lives of millions of people. Each year, 5 million patients benefit from Medtronic's technology, used to treat conditions such as diabetes, heart disease, neurological disorders, and vascular illnesses.
710 Medtronic Pkwy
Minneapolis, MN 55432-5604
News | Heart Valve Technology| November 08, 2017
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
News | Heart Valve Technology| November 07, 2017
November 7, 2017 — Medtronic plc recently presented positive data for its self-expanding Intrepid...
News | Heart Valve Technology| October 23, 2017
October 23, 2017 — The first patient implant has taken place in the APOLLO Trial, the pivotal trial designed to evalu
News | Embolization devices| October 16, 2017
October 16, 2017 — Medtronic announced the launch of the Concerto 3-D Detachable Coil System at the Cardiovascular an
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
News | Renal Denervation| August 31, 2017
Medtronic plc announced its intent to move forward with a new renal denervation pivotal trial following positive first...
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...